Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Abatacept-Associated behavioral, inflammatory, and immunohistochemical changes in a rotenone-induced rat model of parkinsonism.

Created on 16 Nov 2026

Authors

Fatma Nihan Cankara, Mustafa Nusret Çiçekli, Ahmet Altun, Özlem Özmen, Arjan Kortholt

Published in

Molecular biology reports. Volume 53. Issue 1. Nov 15, 2026. Epub Nov 15, 2026.

Abstract

Neuroinflammation and peripheral immune dysregulation are implicated in Parkinson's disease, supporting evaluation of immunomodulatory interventions. We investigated outcomes associated with abatacept administered before rotenone exposure, alone or combined with L-DOPA/benserazide administered concurrently with rotenone, in a rat model of parkinsonism.
Thirty male Wistar rats were randomly assigned to five groups: control, rotenone, rotenone plus abatacept, rotenone plus L-DOPA/benserazide, and combined treatment. Rotenone and L-DOPA/benserazide were administered concurrently for 14 days; abatacept was administered twice, beginning 48 h before rotenone. Motor performance and serum IL-10 and TNF-α were assessed. TH and pSer129 α-synuclein immunopositivity in the substantia nigra and pSer129 α-synuclein and TNF-α immunopositivity in peripheral tissues were evaluated semi-quantitatively. Compared with rotenone, abatacept increased rearing, ambulation, and serum IL-10 and decreased serum TNF-α, without significantly altering rotarod performance or nigral immunopositivity. L-DOPA improved all motor measures and increased serum IL-10 but did not significantly alter serum TNF-α or nigral immunopositivity. Combined treatment improved all motor measures, increased serum IL-10 and nigral TH immunopositivity, decreased serum TNF-α, and reduced pSer129 α-synuclein immunopositivity in four peripheral tissues and TNF-α immunopositivity in the liver and jejunum. Serum TNF-α was lower with abatacept than with L-DOPA. Compared with L-DOPA, combined treatment additionally affected only ambulation and serum TNF-α.
Abatacept was associated with selected motor and cytokine changes in experimental parkinsonism. Combined treatment showed a broader pattern of changes relative to rotenone, but its advantages over L-DOPA were outcome-specific. Peripheral pSer129 α-synuclein findings represent exploratory changes in immunoreactivity rather than evidence of altered α-synuclein aggregation. These findings, obtained under a pretreatment/concurrent administration design, support further investigation but do not establish therapeutic efficacy after parkinsonian pathology has developed, a generalized combination benefit, or an underlying immune mechanism.

PMID:
43034956
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 12
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement